[{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell Files Patent Application for Novel Immune Therapies for Multiple Disease Indications","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell to Present Clinical Data at 2020 American Society of Clinical Oncology (ASCO) Annual Meeting May 29","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell Continues Business and Clinical Operations During COVID-19 Pandemic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell Presents Clinical Findings at 2020 American Society of Clinical Oncology (ASCO) Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell Announces Presentation of Clinical and Scientific Findings at AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell to Present Clinical Findings at the 2020 San Antonio Breast Cancer Symposium\u00ae, December 9 \u2013 11","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BriaCell Announces Collaboration with the National Cancer Institute","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell Adds Mary Crowley Cancer Research Center as a Clinical Trial Site for its Phase I\/IIa Breast Cancer Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Briacell Advances Preparatory Work for New Bria-ots\u2122 Breast Cancer Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell Presents Development Details of Bria-OTS Platform Technology at the American Association for Cancer Research (AACR) Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Harvard Medical School","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BriaCell Enters Research Agreement to Identify Novel Targets for Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"CANADA","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"University of Wisconsin\u2013Madison","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BriaCell Partners with Waisman Biomanufacturing to Manufacture and Supply Prostate Cancer Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Caris Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BriaCell Partners with Caris Life Sciences\u00ae to Expand Patient Outreach and Molecular Profiling","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CANADA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell to Present New Clinical Data at the 2022 San Antonio Breast Cancer Symposium\u00ae December 6th and 7th","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CANADA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell Announces New Clinical Trial Site to Bring Novel Cancer Treatments to Advanced Breast Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CANADA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell Announces Successful Completion of Phase I Portion of Clinical Study in Advanced Breast Cancer; Randomized Phase II Efficacy Evaluation Progressing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CANADA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inycte","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell CEO Discusses Positive Clinical Results of its Breast Cancer Immunotherapy Treatment in an Audio Interview with SmallCapVoice.com","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CANADA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell Announces New Patent Issuance, Bria-OTS IND Timing Guidance, and Additional Clinical Sites to Boost Enrolment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell Announces Positive End of Phase II Meeting with the FDA for Bria-IMT(TM) Combination in Advanced Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CANADA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell Reports Positive Survival Data in Advanced Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Prevail Partners","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"BriaCell Announces $4 Million Strategic Investment and Clinical Alliance with Prevail Partners, LLC and Prevail InfoWorks, Inc.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Prevail Partners","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"BriaCell Closes $4 Million Strategic Investment by Prevail Partners, LLC at US$8.63 per Share","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves BriaCells Pivotal Registrational Study Design in Advanced Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BriaCell Awarded National Cancer Institute Grant to Advance its Bria-OTS\u2122 Immunotherapy for Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"BriaCell Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BriaCell Therapeutics Corp. Announces Closing of Plan of Arrangement Spinning Out BriaPro Therapeutics Corp. to Existing Shareholders","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell Initiates Pivotal Phase 3 Study of Bria-IMT\u2122 in Advanced Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"NYCBS","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BriaCell Partners with New York Cancer & Blood Specialists (NYCBS) for Pivotal Phase 3 Study of Bria-IMT\u201e\u00a2 in Advanced Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CANADA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate (ADC) Refractory Patient Subset","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"}]
Find Clinical Drug Pipeline Developments & Deals by BriaCell Therapeutics
Bria-IMT (SV-BR-1-GM) is a genetically engineered human breast cancer cell line with features of immune cells. It is being evaluated in phase 3 clinical trials in combination with Zynyz (retifanlimab) for the treatment of advanced metastatic breast cancer.
Bria-Pros+ is a novel off-the-shelf personalized immunotherapy. It is being evaluated in preclinical studies for the treatment of patients with prostate cancer.
Bria-IMT (SV-BR-1-GM) is an off-the-shelf targeted cellular immunotherapy. It is being evaluated in phase 3 clinical trials in combination with Zynyz (retifanlimab-dlwr) for the treatment of Metastatic breast cancer.
The partnership aims to evaluate the Bria-IMT (SV-BR-1-GM), a cell based patented immunotherapy, combination with a checkpoint inhibitor in its pivotal Phase 3 registration study in advanced breast cancer patients in New York.
Bria-IMT™ (SV-BR-1-GM) is a targeted immunotherapy having both indirectly and directly stimulates the body’s own cancer-fighting cells to attack and destroy breast cancer tumors.
Bria-IMT™ (SV-BR-1-GM) is a targeted immunotherapy having both indirectly and directly stimulates the body’s own cancer-fighting cells to attack and destroy breast cancer tumors.
Through the spin-off, certain pipeline assets of BriaCell, including Bria-TILsRx and protein kinase C delta (PKCδ) inhibitors for multiple indications including cancer were spun-out to BriaPro.
The Company intends to use the funds for the development of Bria-OTS™, BriaCell’s novel personalized off-the-shelf immunotherapies for advanced metastatic breast cancer, prostate cancer, lung cancer, and melanoma.
Bria-IMT™ (SV-BR-1-GM) is a targeted immunotherapy having both indirectly and directly stimulates the body’s own cancer-fighting cells to attack and destroy breast cancer tumors.
The financing will be used in BriaCell’s upcoming pivotal study including SV-BR-1-GM, a GM-CSF-secreting breast tumor cell line, in advanced metastatic breast cancer.
Lead Product(s):
SV-BR-1-GM,Cyclophosphamide,Interferon Inoculation
Market Place
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
